COMMUNIQUÉS West-GlobeNewswire

Stryker to announce financial results for its second quarter of fiscal year 2024
01/07/2024
Portage, Michigan, July 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, July 30, 2024. A press release will be issued at [...]
Nexalin Technology Announces Closing of $5.2 Million Public Offering
01/07/2024
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of [...]
A-S Medication Solutions Announces Strategic Transition
01/07/2024
LIBERTYVILLE, Ill., July 01, 2024 (GLOBE NEWSWIRE) -- A-S Medication Solutions (ASM) today announced a strategic transition of its relationship with Triple Aim Consulting, LLC (“TAC”). For a number of years, ASM has had [...]
BioPorto confirms market acceptance of NGAL products with US standing order.
01/07/2024
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: [...]
Protect Pharmaceutical Corp. Issues Corporate Update
01/07/2024
ANKARA, Turkey, July 01, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: "July 1, 2024 Dear [...]
Le CHMP émet un avis favorable pour BALVERSA® (erdafitinib) dans le traitement des patients adultes atteints d’un carcinome urothélial non résécable ou métastatique présentant des altérations génétiques sensibles du FGFR3
01/07/2024
En cas d’approbation, l’erdafitinib deviendrait le premier traitement ciblant les altérations du FGFR3 chez les patients atteints de carcinome urothélial métastatique, l’un des cancers les plus répandus en Europe 1 La [...]
Novo Nordisk A/S - share repurchase programme
01/07/2024
Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®
01/07/2024
Asset acquisition expands Merit’s endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 [...]
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
01/07/2024
ZTlido ® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year. ZTlido ® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the [...]
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
01/07/2024
The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company [...]
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
01/07/2024
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Ricky Williams Applauds NCAA’s Decision to Remove Cannabinoids from Banned Substances List, Emphasizes Need for Education on Cannabis
01/07/2024
LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Ricky Williams, former Heisman Trophy winner, renowned cannabis advocate, and founder of the cannabis brand Highsman, has expressed his strong support for the NCAA's recent [...]
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
01/07/2024
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]
GRI Bio to Present at the 8th Annual IPF Summit
01/07/2024
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the [...]
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
01/07/2024
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute [...]
Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors
01/07/2024
Adding Decades of Public Company and Board Expertise as Prenetics Readies for Expansion into Consumer Health and Wellness LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics [...]
Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements
01/07/2024
MINNEAPOLIS, July 01, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced it has filed its Form 10-Q for the quarter ended March, 31, 2024 and in doing so has regained [...]
Inside information: Orion upgrades full-year outlook for 2024
01/07/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 1 JULY 2024 at 15:15 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for [...]
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
01/07/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 1 JULY 2024 at 15:15 EEST Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an [...]

Pages